Technical420 Site Search

Two Nasdaq traded cannabis companies announced earnings during the last week. These companies, Insys Therapeutics (INSY) and GW Pharmaceuticals (GWPH), are focused on improving daily life for millions of people around the world by developing medicines derived from cannabis.Insys Therapeutics, Inc. (INSY)Insys Therapeutics, Inc. is commercial-stage specialty pharmaceutical company that…

The emergence of the cannabis industry has created a number of wealth building opportunities for investors. There are more 250 publicly traded cannabis companies, however, most of them will dissolve or shut down over the next two years. Today, we are going to discuss 5 companies that every investor should…

GW Pharmaceutical (GWPH: NASDAQ) has quietly outperformed most of its fellow NASDAQ companies during 2015 and Technical420 has been recommending them the whole time. GWPH is up over 15% today and over 63% this year. GWPH is a pharmaceutical company focused on developing treatments derived from cannabis. The company has…

I recently read about a woman who planned to euthanize her dog who that had been suffering from chronic pain after veterinary specialists said it was an incurable condition. The dog would constantly lick her paws and the vets explained that was an involuntary reaction to pain.In a last resort…

GW Pharmaceutical (GWPH: NASDAQ) has quietly outperformed most of its fellow NASDAQ companies during 2015 and Technical420 has been recommending them the whole time. GWPH is up over 10% today and over 36% this year. The company manufactures and sells the first prescribed cannabis-based medicine in over 20 countries and…

Every day there seems to be a new article about the medical benefits associated with marijuana. These benefits create an opportunity that cannabis cultivators are trying to capitalize on.  Once these growers find a strain that combats a certain illness, they try and patent it. From 1989 to 2013, the…

One of the most frequently asked questions I have received over the last year pertains to how an investor can diversify their portfolio of cannabis stocks. A year ago, I would have said that it is impossible to be diversified in an industry filled with non-reporting, unregulated, developmental companies.Today, the theory…

Insys Therapeutics, Inc. (INSY) announced that the FDA granted the Fast Track designation to its CBD formulation for the treatment of Dravet’s syndrome. INSY’s new, DEA-inspected facility will allow the company to manufacture mass quantities of CBD for its research and commercial plans."Coupled with our candidate's orphan drug designation in…

Less than two weeks ago, Michael Berger, president of Technical420, hosted a panel of marijuana experts at the World Moneyshow in Orlando. The panel included experts that serve in a number of subsectors in the cannabis industry. The panelists were Stephen Schultz, the vice president of investor relations at GW Pharmaceutical (GWPH:…

The marijuana industry is at a turning point. The major catalyst for the marijuana industry during 2015 is the rescheduling of marijuana out of its current Schedule I classification. In late October, U.S District Judge Kimberly Mueller listened to testimonies during a five day evidentiary hearing aimed at determining if…